Biologics & Biosimilars: Where Do We Go From Here?

The NYIPLA’s Fifth Annual Biosimilars Panel will bring together industry leaders and experienced practitioners to discuss the future of biologics and biosimilars under the new administration, as well as important developments in case law and legislation during the pandemic. Join the conversation and virtually connect with your colleagues on March 10 to discuss the outlook for new legislation under the Biden administration, recently enacted changes to the Purple Book, and the impact of the pandemic, and important case law developments in 2020. 

SPEAKERS:

• Raymond Doss, Senior Counsel, Amgen 
• Karin Hessler, Vice President & Deputy General Counsel, Association for Accessible Medicine
• Margareta Sorenson, Director of Intellectual Property, Amicus Therapeutics
• Rachel Turow, Associate General Counsel, Teva Pharmaceutical Industries Ltd. 
• Moderator Huiya Wu, Partner, Goodwin Procter 

CLE MATERIAL:

• CLE Evaluation Form (1 Page)
• Biologics & Biosimilars Presentation (57 Pages)
• Speaker Biographies (5 Pages)

 EARN 1.5 PROFESSIONAL CLE CREDIT

Hosted by the NYIPLA Patent Litigation and Women in IP Law Committees